1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Prostate Cancer Disappointment Means Lilly Might Finally Get The Point

 
• By Elizabeth Cairns

Point Biopharma’s radiopharmaceutical lags Novartis’s on PFS, and its commercial viability may be limited.  

Unhappy and disappointed customer giving low rating and negative feedback in survey, poll or questionnaire. Sad and dissatisfied man giving review about service quality. Bad user experience. - Image

After months of waiting, Eli Lilly and Company might soon get its hands on the radiopharmaceutical specialist POINT Biopharma Global Inc.. In October, Lilly bid $1.4bn to acquire Point, but the majority of the smaller group’s investors declined to tender their shares. It is likely that they wanted to wait for data from the Phase III trial of Point’s prostate cancer radioligand PNT2002; if this were to be a huge success, Point’s shareholders could demand Lilly up its bid.

Key Takeaways
  • The SPLASH trial of Point Biopharma’s radiopharmaceutical PNT2002 yielded disappointing results

If that was indeed the thinking, the data that came yesterday could change the situation. PNT2002’s SPLASH trial hit, but...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

More from R&D

Ireland’s Got Biopharma Talent To Keep Leading The Pack

 
• By Kevin Grogan

The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.